

**Product Name** : Dabrafenib  
**Cat. No.** : PC-24572  
**CAS No.** : 1195765-45-7  
**Molecular Formula** : C<sub>23</sub>H<sub>20</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>S<sub>2</sub>  
**Molecular Weight** : 519.56  
**Target** : Raf  
**Solubility** : 10 mM in DMSO



## Biological Activity

Dabrafenib (GSK2118436) is potent, selective ATP-competitive inhibitor of Raf with IC<sub>50</sub> of 5 nM and 0.6 nM for C-Raf and B-Raf V600E respectively, also potently inhibits RIPK3 with IC<sub>50</sub> of 28 nM.

Dabrafenib displayed highly selective inhibition on RIP3 over RIP1, RIP2 and RIP5.

Dabrafenib rescued cells from RIP3-mediated necroptosis induced by the necroptosis-induced combinations, that is, tumor necrosis factor (TNF) $\alpha$ , TNF-related apoptosis-inducing ligand or Fas ligand plus Smac mimetic and the caspase inhibitor z-VAD.

Dabrafenib decreased the RIP3-mediated Ser358 phosphorylation of mixed lineage kinase domain-like protein (MLKL) and disrupted the interaction between RIP3 and MLKL.

## References

Hong DS, et al. Clin Cancer Res. 2012 Apr 15;18(8):2326-35.

Falchook GS, et al. Lancet. 2012 May 19;379(9829):1893-901.

Greger JG, et al. Mol Cancer Ther. 2012 Apr;11(4):909-20.

Li JX, et al. Cell Death Dis. 2014 Jun 5;5(6):e1278.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com